Science & Health
1 просмотров
Lecanemab study shows 35% slower cognitive decline in early Alzheimer's patients
An experimental Alzheimer's treatment has posted a notable result in a late-stage trial, with researchers reporting that lecanemab slowed cognitive decline by 35% in people with early-stage disease.…
5ч назад